One research note from Tuesday suggest that the great gains from Biogen Idec are done. With shares around $152.65 now, Canaccord Genuity has initiated the MS-leader in biotech with a Hold rating. If you consider that the price target objective is only $144 for the next 12-months, that Hold rating may sound like more of a Sell rating. Canaccord Genuity said that it expects a slower than consensus BG-12 launch, but ultimately it does see blockbuster potential. The firm also noted:
- Hemophilia franchise potential is large given data so far, but await full Phase 3 data for safety, efficacy detail. Top-line A-LONG and B-LONG trial data were positive, suggesting BIIB’s long-lasting Fc factors could significantly reduce infusion frequency in hemophilia A and B patients. With top-line data only, however, we are tempering our enthusiasm as we await full details to flesh out the drugs’ safety profile and clinical potential.
- We see low likelihood of EMPOWER success given lack of iron-clad Phase 2 data and difficulty in ALS drug development. We believe the complexity of ALS, EMPOWER trial design and noisiness of Phase 2 data together reduce the trial’s chance of success. Given the lack of ASL treatments, however, we think positive Phase 3 data would provide meaningful upside.
- Pipeline: daclizumab, anti-LINGO, others could create long-term value. While we expect weakness on BG-12 launch, we think BIIB’s pipeline will create significant long-term value. For investors with a 12-month+ horizon, we think BG-12-driven weakness could be a good entry point.
As far as what this means with a current price of $152.65, the 52-week trading range is $109.22 to $157.18. Thomson Reuters has a consensus price target of about $159.23, although we would note that the street-high price target is $184 on Biogen Idec.
JON C. OGG
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.